Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Sukaina Virji
A NICE knock-back for Ipsen's Cabometyx in renal cell carcinoma (RCC) means less pressure on BMS's embattled Opdivo, but not for long if Ipsen is willing to compromise on price, warn analysts.
Latecomer Tecentriq from Roche has been making solid in roads in the lung cancer space, where it has been scrapping it out with Bristol-Myers Squibb's Opdivo and Merck & Co's Keytruda. However, early data with Tecentriq in the renal cell carcinoma (RCC) space are less than impressive. The news will be welcomed by BMS, which has Opdivo approved in advanced RCC.
Immunology- and inflammation-focused biotech companies wondering if a trade exit is in their future will be interested to read that, according to a report from Datamonitor Healthcare, their demographic is the most popular acquisition target of the mid-size pharma cohort.
Chi-Med is on course to successfully hit the first of a series of value inflection points slated for 2017. Savolitinib, an inhibitor of c-Met receptor tyrosine kinase partnered with AstraZeneca, has shown early clinical benefit in multiple cancers including a large subset of renal cell carcinoma, and a pivotal Phase III trial is now being planned.
Ipsen has picked up five of Sanofi's consumer healthcare products in certain European markets to enable the larger company's deal with Boehringer Ingelheim to proceed. Despite moves by Ipsen to bolster its cash-generating primary care business, some analysts still believe a sale could make good business sense.
A group of leading researchers are suggesting that using academic centers to de-risk cancer drug discovery could tackle the problem of 'unsustainable drug prices'.